Jefferies initiated coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating given a better risk-reward profile ahead of late-stage data for its lead drug candidate targeting Dravet syndrome, a ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Market OverviewThe global Epilepsy Drugs Market is valued at USD 10.63 billion in 2024 and is projected to reach a value ...

DelveInsight’s Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline ...

A new multicenter study has found that highly purified cannabidiol (CBD) significantly reduces seizure frequency in patients with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous ...